Product Name: GSK3 alpha Antibody
Species Reactivity: Human
Tested Applications: IHC-P, WB
Applications: For WB starting dilution is: 1:1000
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 51 kDa
Immunogen: This GSK3 alpha (GSK3A) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 448-478 amino acids from the C-terminal region of human GSK3 alpha (GSK3A).
Host Species: Rabbit
Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Physical State: Liquid
CAS NO.: 77603-42-0
Abiraterone
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration:
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Glycogen synthase kinase-3 alpha, GSK-3 alpha, Serine/threonine-protein kinase GSK3A, GSK3A
Accession NO.: P49840
Protein Ino: 12644292
Official Symbol: GSK3A
Geneid: 2931
Background: Glycogen synthase kinase 3-alpha (GSK3A)is a multifunctional protein serine kinase implicated in the control of several regulatory proteins including glycogen synthase and transcription factors. It also plays a role in the WNT and PI3K signaling pathways.1 Under resting conditions GSK3A and its homologs are highly phosphorylated at tyr279 in the phosphorylation loop.2 Constitutive phosphorylation of this tyrosine is important for kinase activity. Dephosphorylation of tyr279 after mitogen activation is accompanied by kinase inactivation. PKA as well as PI3K-activated PKB inactivate GSK3A by phosphorylation at ser21.3 Lysophosphatidic acid primarily utilizes a PKC-dependent pathway to modulate GSK3 and certain growth factors (e.g., PDGFB), which control GSK3 mainly through PIK3-PKB, are able to regulate GSK3 through an alternative, redundant phospholipase-C-gamma-PKC pathway.4 Alzheimer disease (AD) is associated with increased production and aggregation of amyloid-beta-40 and -42 peptides into plaques. GSK3A is required for maximal production of the beta-amyloid-40 and -42 peptides generated from the amyloid precursor protein (APP) by presenilin (PSEN1)-dependent gamma-secretase cleavage.5 In vitro, lithium, a GSK3A inhibitor, blocked the production of the beta-amyloid peptides by interfering with the gamma-secretase step. In mice expressing familial AD-associated mutations in APP and PSEN1, lithium reduced the levels of beta-amyloid peptides GSK3A also phosphorylates the tau protein (MAPT), the principal component of neurofibrillary tangles in AD, and suggested that inhibition of GSK3A may offer a new therapeutic approach to AD.
PubMed ID:http://aac.asm.org/content/20/3/366.abstract
